Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
Authors' conclusion
Multimorbidity in patients with RA was associated with greater DAS28 scores within the first two years after ts/bDMARD initiation, in comparison with patients without multimorbidity.
Study context
- Population
- Patients with Rheumatoid Arthritis (RA) from the BIOBADASER registry exposed to a first ts/bDMARD
- Participants
- 1,128 patients
- Exposure
- Multimorbidity (Charlson Comorbidity index (CCI) ≥ 3) vs no multimorbidity (CCI < 3) at baseline in RA patients starting a first ts/bDMARD
- CCI ≥ 3n = 107
- Outcome
- Effectiveness of the first ts/bDMARD: absolute DAS28 score over time after initiation
- Follow-up
- 2 years
Methodological detailslinear regression adjusted for sex and age, Kaplan-Meier and Log-Rank test
- Linear regression adjusted for sex and age
- Kaplan-Meier and Log-Rank test
Main finding
As reported in the abstract
Absolute DAS28 over 2 years after ts/bDMARD initiation (linear regression, adjusted for age and sex)
Significantly higher DAS28 over 2 years in patients with multimorbidity (CCI ≥ 3), beta coefficient
0.33
95% CI 0.07–0.58
Observational data: associations, not effects.
Further findings
| Outcome | CCI ≥ 3 | CCI < 3 | P value |
|---|---|---|---|
| Retention rate of first ts/bDMARD, medianNo differences between groups | median 5.68-5.62 | median 6.94-6.96 years | P = 0.610 |
Original publication
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry. Arthritis Res Ther. Published 23 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →